Greenwich Lifesciences Valuation
| GLSI Stock | USD 12.87 0.30 2.39% |
At this time, the firm appears to be undervalued. Greenwich Lifesciences retains a regular Real Value of $19.16 per share. The prevalent price of the firm is $12.87. Our model calculates the value of Greenwich Lifesciences from evaluating the firm fundamentals such as Return On Asset of -0.72, shares owned by insiders of 52.92 %, and Return On Equity of -1.24 as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Greenwich Lifesciences' valuation include:
Undervalued
Today
Please note that Greenwich Lifesciences' price fluctuation is not too volatile at this time. Calculation of the real value of Greenwich Lifesciences is based on 3 months time horizon. Increasing Greenwich Lifesciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Greenwich Lifesciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Greenwich Stock. However, Greenwich Lifesciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 12.87 | Real 19.16 | Target 38.0 | Hype 12.88 |
The intrinsic value of Greenwich Lifesciences' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Greenwich Lifesciences' stock price.
Estimating the potential upside or downside of Greenwich Lifesciences helps investors to forecast how Greenwich stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Greenwich Lifesciences more accurately as focusing exclusively on Greenwich Lifesciences' fundamentals will not take into account other important factors: When choosing an evaluation method for Greenwich Lifesciences, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using all methods to arrive at a better estimate.
Greenwich Lifesciences Cash |
|
Greenwich Valuation Trend
Greenwich Lifesciences' real value analysis enables investors to forecast the earnings more efficiently. Using both Greenwich Lifesciences' enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing decisions.
Greenwich Lifesciences Total Value Analysis
Greenwich Lifesciences is currently projected to have valuation of 159.41 M with market capitalization of 169.17 M, debt of 294.41 K, and cash on hands of 15.64 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Greenwich Lifesciences fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
159.41 M | 169.17 M | 294.41 K | 15.64 M |
Greenwich Lifesciences Asset Utilization
One of the ways to look at asset utilization of Greenwich is to check how much profit was generated for every dollar of assets it reports. Greenwich Lifesciences retains a negative application of resources of -0.72 (percent), losing $0.007245 for each dollar of resources held by the firm. Inadequate asset utilization attests that the company is being less effective with each dollar of resources it retains. Simply put, asset utilization of Greenwich Lifesciences shows how discouraging it operates for each dollar spent on its resources.Greenwich Lifesciences Ownership Allocation
The market capitalization of Greenwich Lifesciences is $169.17 Million. Greenwich Lifesciences secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.Greenwich Lifesciences Profitability Analysis
Net Loss for the year was (8.89 M) with profit before overhead, payroll, taxes, and interest of 0.About Greenwich Lifesciences Valuation
An absolute valuation paradigm, as applied to Greenwich Stock, attempts to find the value of Greenwich Lifesciences based on its fundamental and basic technical indicators. By analyzing Greenwich Lifesciences's financials, quarterly and monthly indicators, and their related drivers, such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Greenwich Lifesciences's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Greenwich Lifesciences. We calculate exposure to Greenwich Lifesciences's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Greenwich Lifesciences's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -3.3 K | -3.4 K |
Greenwich Lifesciences Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 12.8 M | |
| Shares Float | 5.9 M |
Greenwich Lifesciences Current Valuation Indicators
Valuation refers to the process of determining the present value of Greenwich Lifesciences and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Greenwich we look at many different elements of the entity such as Greenwich's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Greenwich Lifesciences, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Greenwich Lifesciences' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Greenwich Lifesciences' worth.Complementary Tools for Greenwich Stock analysis
When running Greenwich Lifesciences' price analysis, check to measure Greenwich Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Greenwich Lifesciences is operating at the current time. Most of Greenwich Lifesciences' value examination focuses on studying past and present price action to predict the probability of Greenwich Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Greenwich Lifesciences' price. Additionally, you may evaluate how the addition of Greenwich Lifesciences to your portfolios can decrease your overall portfolio volatility.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |